Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01851200
Other study ID # FM-12-GCT01
Secondary ID 2012-004508-36
Status Completed
Phase Phase 2
First received April 20, 2013
Last updated February 6, 2018
Start date May 2013
Est. completion date September 2017

Study information

Verified date April 2016
Source Fondazione Michelangelo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the activity of Brentuximab vedotin in refractory germ cell tumors.


Description:

Complete responses with third-line or later salvage chemotherapy (CT) for germ cell tumors (GCT) range 0% to 10% and are usually short-lived and nearly all patients (pts) progressing after multiple courses or high-dose CT will ultimately die from progressive disease.

Cluster of Differentiation antigen-30 (CD30) is expressed by untreated embryonal carcinoma (ECA) thus lending support to a rationale for a targeted approach. The investigators retrospectively re-assessed ECA to strongly retain CD30 staining in most cases (>70%), even after multiple courses or high-dose CT. Moreover, a negative prognostic value of CD30 expression by residuals after CT, particularly in the salvage setting, was set. Brentuximab vedotin is an antibody-drug conjugate consisting of the chimeric anti-CD30 antibody chemically conjugated to an antitubulin synthetic analog (MMAE).

Proof of activity will provide rationale for developing first-line chemo-immunotherapy or maintenance immunotherapy for selected high-risk pts. The primary objective of the study will be the activity of Brentuximab vedotin in refractory GCT. Secondary objectives will include safety and survival.

24 pts with biopsy-proven CD30 positive GCT will receive intravenous Brentuximab vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity. Further eligibility requirements will include failure of 2 or 3 platinum-based CT (prior high-dose CT is allowed). All pts will undergo measurement of serum tumor markers, a computed tomography and a positron emission tomography (PET) scan every weeks. An optimal Simon's 2-stage design will be applied. The primary endpoint is the objective response-rate (ORR). An ORR of 5% is not promising, while a 25% rate will be promising. In stage 1, 9 evaluable patients will be accrued. The type I and II error are both set at 10%.

Additional post-treatment tissue will be available for pts undergoing surgery in the treatment time-course. Tissue array blocks will be constructed from samples of all pts. Assessment will include mutational analysis of most-frequently mutated genes. Two serum aliquots will be collected at baseline and during/end of treatment to assess circulating CD30.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date September 2017
Est. primary completion date August 2017
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age of at least 18 years.

- Confirmation of germ cell tumor histology based on pathologic review at the study site.

- Presence of a CD30 positive embryonal carcinoma component.

- Unequivocal progression of measurable disease.

- A minimum of 2 and a maximum of 3 platinum-based chemotherapy lines for metastatic disease EXCEPT for primary mediastinal germ cell tumors where failure of first-line chemotherapy only is accepted.

- Prior high dose chemotherapy with hematopoietic stem cell rescue is allowed.

Exclusion Criteria:

- Failure to meet any of the above inclusion criteria.

- Patients with late-relapse (defined as relapse occurring after at least 2 years from the date of completion of the last chemotherapy regimen) whose disease is completely surgically resectable (and for whom initial surgical extirpation is recommended) are ineligible. Patients with unresectable late disease relapse are eligible.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Brentuximab Vedotin
Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity

Locations

Country Name City State
Italy Fondazione IRCCS Istituto Nazionale dei Tumori Milano Mi

Sponsors (3)

Lead Sponsor Collaborator
Fondazione Michelangelo Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Metabolic response to Brentuximab Vedotin measured by means of a Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) scan. Six weeks after the first administration of the study drug.
Primary The number of objective responses (partial and complete responses) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 integrated with response of serum tumor markers. Six weeks after the first administration of the study drug.
Secondary Progression-Free Survival 3 months after the initiation of study treatment
Secondary Overall Survival Six months after the initiation of study treatment
Secondary Incidence of adverse events related to the study drug Six weeks after the initiation of the study drug and every 6 weeks thereafter up to 16 weeks.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00996710 - Genomic Structural Variation in Cancer Susceptibility
Active, not recruiting NCT01453660 - Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls
Completed NCT01242631 - Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer Phase 2
Not yet recruiting NCT06275854 - YASU Research Registry: For Young Adults With Cancer
Recruiting NCT04897321 - B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Phase 1
Completed NCT02303015 - Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors
Not yet recruiting NCT06329323 - SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours

External Links